-

Croma-Pharma GmbH expands its portfolio introducing pure HA

Hyaluronic acid without distraction

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma is always committed to deepening its product portfolio to support customers in their daily work. With pure HA, Croma has developed a highly concentrated liquid skin mask in a minimalistic formula containing 1.8% of hyaluronic acid to smooth, moisturize and revitalize the skin while boosting its natural hydration.

Containing ingredients normally used in medical and aesthetic practices, Croma wants to bring the usual high quality of pharma grade hyaluronic acid to skincare used at home. Pure and without distraction.

"With pure HA, we have developed a skincare product based on hyaluronic acid that complies with the high standards of our medical devices, complements our existing portfolio perfectly and underlines Croma's claim as an expert in hyaluronic acid", remarked Andreas Prinz, Managing Director of Croma.

With a silky, lightweight texture suitable for all skin types, pure HA aims to make the skin feel nourished and radiant. Produced in a sterile and high professional glass container, pure HA brings a pharmaceutical approach to skincare at home – from the experts of hyaluronic acid.

About Hyaluronic Acid

Hyaluronic acid is one of the most essential ingredients in skincare today. Hyaluronic acid revitalizes the skin and at the same time strengthens its natural moisture content. It optimizes the skin's elasticity, plumps the skin and improves the appearance of fine lines and wrinkles.

About Croma-Pharma GmbH

Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and innovative skincare technologies in its core strategic markets.

Contacts

CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at

Croma-Pharma GmbH


Release Summary
With pure HA, Croma has developed a highly concentrated liquid skin mask in a minimalistic formula containing 1.8% of hyaluronic acid.

Contacts

CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at

Social Media Profiles
More News From Croma-Pharma GmbH

Croma-Pharma Expands Its Portfolio in Canada With saypha® lips Lidocaine and Exprecell™

LEOBENDORF, Austria & TORONTO--(BUSINESS WIRE)--Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they...

Croma-Pharma Introduces saypha® volume prime Lidocaine

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and ev...

Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the...
Back to Newsroom